The Most Recent Clinical Trial
A Phase IIIa Clinical Study Which Demonstrates Efficacy in Stage II Colon Cancer Patients
A randomized, 254-patient Phase IIIa clinical trial for OncoVAX® at twelve different hospitals in The Netherlands has been completed. The results, published in The Lancet and in Vaccine, demonstrated a statistically significant increased 5-year overall survival rate and increased recurrence-free survival by log-rank analysis, as well as a dramatic increase in the time to tumor progression rate in treated patients. At a median follow-up period of 5.8 years for Stage II colon cancer patients, the Kaplan-Meier 5-year recurrence-free survival rate was increased 41% with a 21.3% death / recurrence rate for the patients treated with OncoVAX®, compared to 37.7% for the surgery-alone control group (p-value of 0.008). Treated patients also demonstrated a statistically significant 33% increase in 5-year overall survival (p-value of 0.014) and an 80% reduction tumor progression rate at 18 months following treatment with OncoVAX®.